Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme. The deficiency of this enzyme accumulates the specific glycosaminoglycans (GAG), keratan sulfate, and chondroitin-6-sulfate mainly in bone, cartilage, and its extracellular matrix. GAG accumulation in these lesions leads to unique skeletal dysplasia in MPS IVA patients. Clinical, radiographic, and biochemical tests are needed to complete the diagnosis of MPS IVA since some clinical characteristics in MPS IVA are overlapped with other disorders. Early and accurate diagnosis is vital to optimizing patient management, which provides a better quality of life and prolonged life-time in MPS IVA patients. Currently, enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) are available for patients with MPS IVA. However, ERT and HSCT do not have enough impact on bone and cartilage lesions in patients with MPS IVA. Penetrating the deficient enzyme into an avascular lesion remains an unmet challenge, and several innovative therapies are under development in a preclinical study. In this review article, we comprehensively describe the current diagnosis, treatment, and management for MPS IVA. We also illustrate developing future therapies focused on the improvement of skeletal dysplasia in MPS IVA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Autophagy in lysosomal storage disorders
Lieberman, A. P., Puertollano, R., Raben, N., Slaugenhaupt, S., Walkley, S. U., & Ballabio, A. (2012) · Autophagy · doi:10.4161/auto.19469 · Cited by 399
Microvesicle-associated AAV Vector as a Novel Gene Delivery System
Maguire, C. A., Balaj, L., Sivaraman, S., Crommentuijn, M. H., Ericsson, M., Mincheva-Nilsson, L., Baranov, V., Gianni, D., Tannous, B. A., Sena-Esteves, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.303 · Cited by 283
Fraldi, A., Annunziata, F., Lombardi, A., Kaiser, H., Medina, D. L., Spampanato, C., Fedele, A. O., Polishchuk, R., Sorrentino, N. C., Simons, K., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.237 · Cited by 225
Lysosomal multienzyme complex: Biochemistry, genetics, and molecular pathophysiology
Pshezhetsky, A. V., & Ashmarina, M. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)69045-7 · Cited by 131 · cited 1×
“In the lysosome, GALNS is stabilized in a complex that includes other enzymes such as β-galactosidase, α neuraminidase [34], and cathepsin A [26].”
BackgroundTordo, J., O’Leary, C., Antunes, A. S. L. M., Palomar, N., Aldrin-Kirk, P., Basche, M., Bennett, A., D’Souza, Z., Gleitz, H., Godwin, A., et al. (2018) · Brain · doi:10.1093/brain/awy126 · Cited by 113
Pshezhetsky, A. V., & Potier, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28359 · Cited by 90 · cited 3×
“Most MPS IVA patients usually look healthy at the neonatal period; however, bone abnormalities in the spine can be seen through X-rays even at birth in a severe form of patients with MPS IVA [26].”
BackgroundSelot, R., Arumugam, S., Mary, B., Cheemadan, S., & Jayandharan, G. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00441 · Cited by 20
Cited by
Amelogenesis imperfecta: Next-generation sequencing sheds light on Witkop’s classification
Bloch-Zupan, A., Rey, T., Jimenez-Armijo, A., Kawczynski, M., Kharouf, N., O-Rare consortium, Dure-Molla, M. D. L., Noirrit, E., Hernandez, M., Joseph-Beaudin, C., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1130175 · Cited by 74
Syndromic retinitis pigmentosa.
Karuntu, J. S., Almushattat, H., Nguyen, X.-T.-A., Plomp, A. S., Wanders, R. J. A., Hoyng, C. B., van Schooneveld, M. J., Schalij-Delfos, N. E., Brands, M. M., Leroy, B. P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101324 · Cited by 39
Piechnik, M., Amendum, P. C., Sawamoto, K., Stapleton, M., Khan, S., Fnu, N., Álvarez, V., Pachon, A. M. H., Danos, O., Bruder, J. T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012693 · Cited by 28
“Even though HSCT shows some impact on the improvement of bone and cartilage pathology, the approach is associated with other limitations such as the risk of graft versus host disease (GVHD), challenges in donor matching, graft rejection, and the need for well-trained staff and suitably equipped clinical facility for s…”
BackgroundMethodSelf-citation
Metadata
- Authors
- Sawamoto, K., Álvarez González, J., Piechnik, M., Otero, F., Couce, M., Suzuki, Y., & Tomatsu, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-02-23
- Volume
- 21
- Issue
- 4
- Pages
- 1517
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3007101482
- Cited by
- 129
- References
- 10
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management. https://app.cochat.ai/papers/10.3390/ijms21041517
- The paper
- Sawamoto, K., Álvarez González, J., Piechnik, M., Otero, F., Couce, M., Suzuki, Y., & Tomatsu, S. (2020). Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21041517
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.